Breaking News Instant updates and real-time market news.

AGN

Allergan

$129.65

-1.32 (-1.01%)

, ABBV

AbbVie

$78.41

-0.37 (-0.47%)

09:07
06/25/19
06/25
09:07
06/25/19
09:07

Fly Intel: Pre-market Movers

HIGHER: Allergan (AGN), up 31% after entering into a definitive transaction agreement under which AbbVie (ABBV) will acquire the company in a cash and stock transaction for an equity value of approximately $63B... Pyxus (PYX), up 15% after Imperial Capital analyst Mary Ross Gilbert initiated the stock with an Outperform rating and $71 price target, citing her view of the potential of the company to be a fast growing franchise for years given its combination of cultivation, extraction and e-liquids capabilities... ArQule (ARQL), up 3% after its 9.25M share spot secondary priced at $9.75 per share. UP AFTER EARNINGS: Lennar (LEN), up 4%. LOWER: AbbVie, down 10% after announcing its $63B cash and stock deal to acquire Allergan... Brighthouse Financial (BHF), down 9% after Credit Suisse analyst Andrew Kligerman downgraded shares to Underperform and Goldman Sachs analyst Alex Scott downgraded the stock to Sell... Pivotal Software (PVTL), down 3% after BofA/Merrill Lynch analyst Nikolay Beliov downgraded the stock to Underperform... Sally Beauty (SBH), down another 3% after yesterday's announcement of the launch of Amazon's (AMZN) professional beauty store... Aldeyra (ALDX), down 24% after reporting statistical significance was not achieved for endpoints in its SOLACE trial.

AGN

Allergan

$129.65

-1.32 (-1.01%)

ABBV

AbbVie

$78.41

-0.37 (-0.47%)

PYX

Pyxus

$13.42

-1.1 (-7.58%)

ARQL

ArQule

$10.00

-0.48 (-4.58%)

LEN

Lennar

$51.41

0.09 (0.18%)

BHF

Brighthouse Financial

$38.10

-0.01 (-0.03%)

PVTL

Pivotal Software

$11.35

-0.15 (-1.30%)

SBH

Sally Beauty

$12.30

-2.49 (-16.84%)

ALDX

Aldeyra

$7.08

-0.29 (-3.93%)

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 27

    Jun

  • 28

    Jun

  • 11

    Jul

  • 16

    Sep

  • 25

    Jun

AGN Allergan
$129.65

-1.32 (-1.01%)

06/25/19
MZHO
06/25/19
NO CHANGE
Target $171
MZHO
Buy
Allergan price target lowered to $171 from $194 at Mizuho
Mizuho analyst Irina Koffler lowered her Botox Cosmetic and CoolSculpt estimates after conducting a survey of 20 dermatologists and plastic surgeons, who gave the impression that that the Botox franchise will be pressured by Evolus (EOLS) and other new entrants. Koffler cut her price target on Allergan shares to $171 from $194 based on the lowered estimates, but maintains a Buy rating on the stock, stating that it is "widely expected" that the company will make a strategic announcement that begins the preliminary work of separating the company in the next 1-2 months.
06/25/19
PIPR
06/25/19
NO CHANGE
PIPR
Neutral
Piper says 'willing to listen' to AbbVie reasoning for Allergan acquisition
Ahead of the call to discuss AbbVie's (ABBV) planned $63B acquisition of Allergan (AGN), Piper Jaffray analyst Christopher Raymond said his first reaction to the deal could be summed up with the phrase "two turkeys don't make an eagle," but he is "willing to listen" despite his skepticism about the transaction. Though he cannot say he is "excited at the prospect of AbbVie entering the field of medical aesthetics," EPS accretion of 10% in year one and over 20% at peak, and the potential for meaningful deleveraging and cost cutting, has his attention, Raymond said. He keeps a Neutral rating on AbbVie based on his initial reaction to the deal announcement.
06/25/19
WELS
06/25/19
NO CHANGE
WELS
Outperform
Deals with premiums like Allergan's 'rarely killed,' says Wells Fargo
After Abbvie (ABBV) announced an agreement to acquire Allergan (AGN) for $120 per share of cash and a remaining $68 in AbbVie shares, Wells Fargo analyst David Maris said he views the deal as a good alternative for Allergan versus the current share price, but he is not convinced its a better long term alternative given the eventual biosimilar threat to Abbvie's blockbuster drug Humira. With that said, Maris tells investors that "deals at such premiums are rarely killed because of a bad strategic fit or longer -term value outlook in the absence of other bidders." Though he would not completely rule out an activist investor disrupting the deal, he thinks it is unlikely given there has been a strategic review of the company for some time. Maris, who said he thinks the deal could go through, keeps an Outperform rating on Allergan shares.
06/25/19
LEER
06/25/19
NO CHANGE
LEER
Outperform
Bid of $188 for Allergan 'too low,' others may pursue as well, says SVB Leerink
SVB Leerink analyst Marc Goodman is not surprise that one of the large pharma companies has made a bid on Allergan (AGN) given the multi-year stock weakness. However, he believes a $188 price is "too low," as he "can't believe that Allergan is not being taken out at least at $200," which "begs the question" whether this was a process or is AbbVie (ABBV) "opportunistically pursuing a wounded stock." If it is the latter, Goodman believes this bid could initiate others to pursue Allergan as well. He has an Outperform rating on Allegan's shares.
ABBV AbbVie
$78.41

-0.37 (-0.47%)

06/13/19
PIPR
06/13/19
NO CHANGE
Target $90
PIPR
Neutral
AbbVie rheumatology franchise feedback incrementally positive, says Piper
Piper Jaffray analyst Christopher Raymond says he sees "incrementally positive feedback" for AbbVie's rheumatology franchise. A new Rheumatologist survey indicates "strong expectations" for the upadacitinib launch, which has an FDA action date of August 19, Raymond tells investors in a research note. The analyst is "compelled" to raise his upadacitinib numbers ahead of approval. However, he keeps a Neutral rating on AbbVie sahres with a $90 price target saying his broader Humira competitive concerns remain in place.
PYX Pyxus
$13.42

-1.1 (-7.58%)

06/25/19
IMPC
06/25/19
INITIATION
Target $71
IMPC
Outperform
Pyxus initiated with an Outperform at Imperial Capital
Imperial Capital analyst Mary Ross Gilbert initiated Pyxus with an Outperform rating and $71 price target, citing her view of the potential of the company to be a fast growing franchise for years given its combination of cultivation, extraction and e-liquids capabilities. She also sees the company having significant financial and operating leverage and thinks the valuation seems conservative compared to Canadian cannabis and hemp companies, Ross Gilbert tells investors.
ARQL ArQule
$10.00

-0.48 (-4.58%)

06/17/19
ROTH
06/17/19
NO CHANGE
Target $20
ROTH
Buy
ArQule price target raised to $20 from $10 at Roth Capital
Roth Capital analyst Tony Butler raised his price target for ArQule to $20 from $10 after the company presented updated data from its first-in-human, single-arm Phase 1 study of ARQ 531, the first oral reversible BTK inhibitor for both wild-type and ibrutinib-resistant BTK-c481S mutation. The analyst reiterates a Buy rating on the shares.
06/14/19
ROTH
06/14/19
NO CHANGE
Target $13
ROTH
Buy
ArQule price target raised to $13 from $10 at Roth Capital
Roth Capital analyst Tony Butler said he is optimistic about the efficacy and safety profile of ARQ 531 following the company's presentation of trial data, investor call and his talk with management. However, he thinks the key uncertainty now is durability of responses, which he highlights as important given the refractory population and the fact that ibrutinib was also based on survival data. He has raised his view of the probability of success for ARQ 531 to 50% from 33% previously and increased his price target to $13 on ArQule shares, on which he keeps Buy rating.
05/29/19
RILY
05/29/19
NO CHANGE
Target $11
RILY
Buy
ArQule price target raised to $11 from $6.75 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for ArQule to $11 from $6.75 ahead of what he expects will be "positive" Phase I safety and efficacy results for ARQ531 at the European Hematology Association conference in June. The analyst reiterates a Buy rating on the shares.
06/19/19
RBCM
06/19/19
NO CHANGE
Target $12
RBCM
Outperform
ArQule price target raised to $12 from $10 at RBC Capital
RBC Capital analyst Gregory Ranza raised his price target on ArQule to $12 and kept his Outperform rating, citing the company's "impressive data" and "high enthusiasm" for its BTKi program ARQ 531 in B-cell malignancies demonstrated at the European Hematology Association Congress this week. The analyst adds that his new price target reflects the improving prospects for ARQ 531 success, along with his "increasing confidence" that an effective path awaits ArQule toward a "meaningful" Chronic Lymphocytic Leukemia market opportunity.
LEN Lennar
$51.41

0.09 (0.18%)

06/18/19
RAJA
06/18/19
DOWNGRADE
RAJA
Underperform
KB Home downgraded to Underperform on 'rich' valuation at Raymond James
Raymond James analyst Buck Horne downgraded KB Home (KBH) to Underperform from Market Perform ahead of the company's earnings report in a move to highlight his increased near-term caution with the homebuilding sector. In a research note to investors, Horne cites factors including above-average cyclical valuations amid declining earnings estimates across the industry, softening macro-economic data points and indicators of a late-cycle shift, and an analysis of recent MSA-level re-sale market statistics suggesting competitive inventory remains elevated into summer for the downgrade. Horne also downgraded Lennar (LEN) to Market Perform from Outperform.
06/18/19
RAJA
06/18/19
DOWNGRADE
Target $55
RAJA
Market Perform
Lennar downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Buck Horne downgraded Lennar to Market Perform from Outperform with a $55 price target saying he sees a "rich" valuation ahead of earnings.
06/17/19
BUCK
06/17/19
NO CHANGE
Target $56
BUCK
Buy
Buckingham 'constructive' on Lennar, KB Home ahead of earnings reports
Buckingham analyst Megan McGrath tells investors in a research note that she remains "constructive" on both Lennar (LEN) and KB Home (KBH) ahead of the companies' earnings report next week, saying she expects both companies to continue to point to improvements in demand trends through the quarter and an easing of incentives vs. Q1 levels. The analyst, who maintains a Buy rating and $56 price target on Lennar and a Neutral rating and $27 price target on KB Home, says she currently prefers Lennar's more diverse regional exposure andfaster absorption pace for a one-year outlook to KB Home's high California exposure and higher debt levels.
06/18/19
RAJA
06/18/19
DOWNGRADE
Target $55
RAJA
Market Perform
Lennar downgraded to Market Perform on 'rich' valuation, says Raymond James
Raymond James analyst Buck Horne downgraded Lennar (LEN) to Market Perform from Outperform with a $55 price target ahead of the company's earnings report in a move to highlight his increased near-term caution with the homebuilding sector. In a research note to investors, Horne cites factors including above-average cyclical valuations amid declining earnings estimates across the industry, softening macro-economic data points and indicators of a late-cycle shift, and an analysis of recent MSA-level re-sale market statistics suggesting competitive inventory remains elevated into summer for the downgrade. Horne also downgraded KB Home (KBH) to Underperform from Market Perform.
BHF Brighthouse Financial
$38.10

-0.01 (-0.03%)

06/03/19
SBSH
06/03/19
NO CHANGE
SBSH
Citi recommends focusing on pair trades in Life Insurance
Citi analyst Suneet Kamath believes investors should consider pair trades within the U.S. Life & Health Insurance space. The analyst favors Voya Financial (VOYA) over Principal Financial Group (PFG), Lincoln National (LNC) over Brighthouse Financial (BHF), and Reinsurance Group (RGA) over Aflac (AFL).
06/25/19
06/25/19
DOWNGRADE
Target $22

Underperform
Brighthouse Financial downgraded to Underperform on risk at Credit Suisse
As previously reported, Credit Suisse analyst Andrew Kligerman downgraded Brighthouse Financial to Underperform from Neutral on risk, and lowered his price target on the shares to $22 from $35. The analyst believes the stock appears expensive given its volatile distributable earnings and new accounting pressure.
06/25/19
FBCO
06/25/19
DOWNGRADE
Target $22
FBCO
Underperform
Brighthouse Financial downgraded to Underperform from Neutral at Credit Suisse
Credit Suisse analyst Andrew Kligerman downgraded Brighthouse Financial to Underperform from Neutral and cut the price target to $22 from $35.
06/25/19
GSCO
06/25/19
DOWNGRADE
Target $32
GSCO
Sell
Brighthouse Financial downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Alex Scott downgraded Brighthouse Financial to Sell from Neutral and lowered his price target on the shares to $32 from $39 as he believes the company's capital plans may come under pressure. Lower interest rates may result in little to no distributable earnings from the variable annuity business, he does not see a material redundancy in the universal life captive and there is still regulatory risk from the updated VA Capital Reform and deductible approach to hedging, all of which will make it harder for subsidiary Brighthouse Life Insurance to begin making ordinary cash remittances to the holding company, Scott tells investors.
PVTL Pivotal Software
$11.35

-0.15 (-1.30%)

06/05/19
FBCO
06/05/19
NO CHANGE
Target $20
FBCO
Outperform
Pivotal Software price target lowered to $20 from $25 at Credit Suisse
Credit Suisse analyst Brad Zelnick lowered his price target for Pivotal Software to $20 from $25 following disappointing Q1 results that sent the stock down nearly 30% in after-hours trading. Results and guidance lead him to believe the shift to containerized architecture and Kubernetes is more disruptive to Pivotal than he originally expected. At the same time, with the stock now trading at 5.6 times EV/Recurring Revenue, Zelnick pivots to a more value-oriented thesis as he believes the equity is now priced in line with the intrinsic value of its installed base business. The analyst reiterates an Outperform rating on the shares.
06/05/19
NEED
06/05/19
NO CHANGE
Target $21
NEED
Buy
Pivotal Software price target lowered to $21 from $28 at Needham
Needham analyst Jack Andrews lowered his price target on Pivotal Software to $21 after its "disappointing" Q1 results, noting that while earnings and revenue topped expectations, billings missed consensus and the company indicated that execution issues led to fewer closed deals. The analyst also lowers his FY21 EPS view to 5c from 17c and expects the stock to "languish" for at least a quarter, but also keeps his Buy rating and expects Pivotal Software's slipped deals to close in the coming quarters. Andrews also cites a "compelling" below 3-times enterprise value to revenue multiple based on the sharp pullback in Pivotal Software stock afterhours.
06/05/19
WEDB
06/05/19
DOWNGRADE
Target $15
WEDB
Neutral
Pivotal Software downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Daniel Ives downgraded Pivotal Software to Neutral from Outperform and lowered his price target on the shares to $15 from $26 following the company's "thesis changing" quarterly results and guidance.
06/25/19
BOFA
06/25/19
DOWNGRADE
Target $12
BOFA
Underperform
Pivotal Software downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill Lynch analyst Nikolay Beliov downgraded Pivotal Software to Underperform from Neutral following the company's "meaningful" revenue guidance miss with its Q1 report. Pivotal is taking the right steps to address its challenges, but addressing them will take some time, said Beliov, who sees the stock underperforming in the next 12 months. He has a $12 price target on Pivotal shares.
SBH Sally Beauty
$12.30

-2.49 (-16.84%)

06/24/19
JEFF
06/24/19
NO CHANGE
JEFF
Sally Beauty 'most exposed' to Amazon news, Ulta not hurt, says Jefferies
After Amazon (AMZN) officially launched a business-to-business platform for professional stylists, Jefferies analyst Stephanie Wissink called Sally Beauty (SBH) "most exposed." The Beauty Systems Group accounts for 40% of Sally's total sales, and nearly 50% of sales at Sally Beauty Supply come from professional stylists, Wissink stated, estimating that 30%-35% of Sally's business could potentially be directly impacted by a shift in stylist orders to Amazon's B2B platform. She expects a neutral impact for beauty companies with professional brands, like Coty (COTY) and L'Oreal (LORLY), and said Amazon's pro platform should have "little impact" on Ulta Beauty (ULTA), which the analyst noted does not offer wholesale value to professional stylists.
06/25/19
OPCO
06/25/19
NO CHANGE
OPCO
Perform
Amazon entrance to likely continue to depress Sally's multiple, says Oppenheimer
Oppenheimer analyst Rupesh Parikh notes that Amazon (AMZN) Business announced the launch of the Amazon Professional Beauty store and that he spoke with Sally Beauty (SBH) management. Given the exclusivity the BSG side of the business has with key brands, the analyst think announcement would have a minimal nearer-term impact on Sally's business. Nonetheless, Parikh believes Amazon's entrance and interest in the category will likely continue to depress Sally Beauty's multiple to even lower levels until the company can demonstrate the ability to return to positive comp growth on a sustainable base. For now, Ulta Beauty (ULTA) and Estee Lauder (EL) remain his top beauty picks. The analyst has a Perform rating on Sally Beauty's shares.
05/07/19
DADA
05/07/19
NO CHANGE
Target $16.5
DADA
Neutral
Sally Beauty price target lowered to $16.50 from $19 at DA Davidson
DA Davidson analyst Linda Bolton Weiser lowered her price target on Sally Beauty to $16.50 and kept her Neutral rating after its Q1 earnings miss and "disappointing" same-store-sales decline reported last week. The analyst notes that the comps at the Sally Beauty segment were down 0.3% after two consecutive quarters of flat/positive growth thanks in part to Brexit-related uncertainty in Europe, and she expects those challenges to persist through the back half of 2019.
06/25/19
DADA
06/25/19
NO CHANGE
Target $14
DADA
Neutral
Sally Beauty price target lowered to $14 from $16.50 at DA Davidson
DA Davidson analyst Linda Bolton Weiser lowered her price target for Sally Beauty (SBH) to $14 from $16.50 following the launch of Amazon's (AMZN) professional beauty store. In a research note to investors, the analyst says she estimates 19% of Sally Beauty's operating profit is directly threatened, with an additional 33% potentially at risk for increased competition.
ALDX Aldeyra
$7.08

-0.29 (-3.93%)

03/26/19
SBSH
03/26/19
NO CHANGE
Target $28
SBSH
Buy
Citi boosts Aldeyra target to $28 from $23, closes catalyst watch
Citi analyst Yigal Nochomovitz closed his 90-day catalyst watch on Aldeyra after the company reported Phase 3 data for reproxalap in allergic conjunctivitis. On February 15, Nochomovitz predicted the stock could be up 75% to 125% on positive data. The analyst today boosted his price target for Aldeyra to $28 from $23 and keeps a Buy rating on the name. The stock in afternoon trading is up 36%, or $2.56, to $9.70.
05/10/19
ADAM
05/10/19
NO CHANGE
Target $20
ADAM
Buy
Aldeyra price target lowered to $20 from $35 at Canaccord
Canaccord analyst John Newman lowered his price target for Aldeyra to $20 from $35 and maintained a Buy rating, saying Aldeyra has enrolled the first patient in the critical Phase 3 dry eye study for reproxalap, testing the 0.25% dose. Newman says he lowered this price target based on more conservative launch timelines, and says he is conservatively assuming launch of reproxalap in 2022 for all indications, some of which may occur sooner.
03/26/19
JONE
03/26/19
NO CHANGE
Target $38
JONE
Buy
Aldeyra price target raised to $38 from $32 at JonesTrading
JonesTrading analyst Matthew Cross raised his price target for Aldeyra Therapeutics to $38 from $32 citing the company's positive results from the Alleviate trial in allergic conjunctivitis for reproxalap. This morning's data set a new precedent in an indication that many on the Street appear to have effectively overlooked, Cross tells investors in a research note. The analyst believes the opportunity in allergic conjunctivitis is greater than that of dry eye, and says multiple aspects of the Phase 3 Alleviate data suggest that both markets may be targeted in tandem with a single reproxalap product and concentration. He sees "nothing to gripe at across endpoints, doses, or safety" and maintains a Buy rating on Aldeyra.
03/26/19
JONE
03/26/19
NO CHANGE
JONE
Buy
Aldeyra price target raised to $38 from $32 at JonesTrading

TODAY'S FREE FLY STORIES

SCBFF

Standard Chartered

$0.00

(0.00%)

13:07
07/19/19
07/19
13:07
07/19/19
13:07
Periodicals
Standard Chartered accused of handling $56.8B in illegal Iran deals, FT says »

Whistleblowers are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSIX

Power Solutions

$0.00

(0.00%)

13:06
07/19/19
07/19
13:06
07/19/19
13:06
Hot Stocks
Former Power Solutions CEO charged with accounting fraud »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$10.38

0.765 (7.96%)

13:05
07/19/19
07/19
13:05
07/19/19
13:05
Options
AMC Entertainment call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

  • 05

    Sep

13:04
07/19/19
07/19
13:04
07/19/19
13:04
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 7/19 Baker-Hughes…

BHGE

Baker Hughes

$23.65

0.34 (1.46%)

13:01
07/19/19
07/19
13:01
07/19/19
13:01
Hot Stocks
Baker Hughes reports U.S. rig count down 4 to 954 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 27

    Aug

12:45
07/19/19
07/19
12:45
07/19/19
12:45
General news
Breaking General news story  »

Week of 7/19 Baker-Hughes…

LYFT

Lyft

$67.78

1.74 (2.63%)

12:43
07/19/19
07/19
12:43
07/19/19
12:43
Hot Stocks
Lyft announces new airport pickup feature starting July 20 at LGA »

In a blog post, Lyft…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

WMT

Walmart

$114.81

0.13 (0.11%)

12:41
07/19/19
07/19
12:41
07/19/19
12:41
Periodicals
Walmart to shuffle executives to further integrate stores and digital, CNBC says »

Walmart is shuffling its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 25

    Sep

  • 13

    Nov

WMT

Walmart

$114.83

0.15 (0.13%)

12:36
07/19/19
07/19
12:36
07/19/19
12:36
Periodicals
Walmart to shuffle executives to further integrate stores and digital, CNBC says »

CNBC's Courtney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 25

    Sep

  • 13

    Nov

NFLX

Netflix

$321.59

-3.55 (-1.09%)

12:29
07/19/19
07/19
12:29
07/19/19
12:29
Periodicals
Eddie Murphy in talks with Netflix over comedy specials, TMZ reports »

Comedian and actor Eddie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

FL

Foot Locker

$42.72

0.35 (0.83%)

12:25
07/19/19
07/19
12:25
07/19/19
12:25
Options
Foot Locker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 19

    Sep

  • 25

    Sep

DIS

Disney

$141.00

-0.62 (-0.44%)

, SNE

Sony

$53.93

-0.02 (-0.04%)

12:21
07/19/19
07/19
12:21
07/19/19
12:21
On The Fly
Box Office Battle: 'Lion King' expected to claim this weekend's throne »

Welcome to "Box Office…

DIS

Disney

$141.00

-0.62 (-0.44%)

SNE

Sony

$53.93

-0.02 (-0.04%)

T

AT&T

$32.91

-0.185 (-0.56%)

CBS

CBS

$51.32

-0.02 (-0.04%)

CMCSA

Comcast

$44.14

-0.42 (-0.94%)

CMCSK

Comcast

$0.00

(0.00%)

LGF.A

Lionsgate

$11.72

0.14 (1.21%)

LGF.B

Lionsgate

$11.05

0.03 (0.27%)

VIA

Viacom

$35.39

0.39 (1.11%)

VIAB

Viacom

$30.79

0.2 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

12:21
07/19/19
07/19
12:21
07/19/19
12:21
Conference/Events
Wolfe Research utilities/midstream analyst to hold a group luncheon »

Utilities & Midstream…

AMRX

Amneal Pharmaceuticals

$3.35

-0.04 (-1.18%)

, BMY

Bristol-Myers

$43.57

-0.47 (-1.07%)

12:18
07/19/19
07/19
12:18
07/19/19
12:18
Hot Stocks
Amneal Pharmaceuticals granted tentative FDA approval of Apremilast »

Amneal Pharmaceuticals…

AMRX

Amneal Pharmaceuticals

$3.35

-0.04 (-1.18%)

BMY

Bristol-Myers

$43.57

-0.47 (-1.07%)

CELG

Celgene

$90.39

-0.51 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 25

    Jul

  • 08

    Aug

  • 03

    Sep

  • 16

    Sep

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
07/19/19
07/19
12:17
07/19/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
07/19/19
07/19
12:16
07/19/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YGTY

SSLJ.com

$1.18

-0.12 (-9.23%)

12:15
07/19/19
07/19
12:15
07/19/19
12:15
Hot Stocks
Breaking Hot Stocks news story on SSLJ.com »

SSLJ com Ltd (Class A…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$374.39

13.22 (3.66%)

, MSFT

Microsoft

$138.27

1.98 (1.45%)

12:10
07/19/19
07/19
12:10
07/19/19
12:10
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are modestly…

BA

Boeing

$374.39

13.22 (3.66%)

MSFT

Microsoft

$138.27

1.98 (1.45%)

AXP

American Express

$125.00

-3.4 (-2.65%)

GCI

Gannett

$9.62

1.72 (21.77%)

CRWD

Crowdstrike

$83.30

10.55 (14.50%)

SKX

Skechers

$39.35

4.6 (13.24%)

MIK

Michaels

$7.75

-0.62 (-7.41%)

PACB

Pacific Biosciences

$5.23

-0.64 (-10.90%)

ILMN

Illumina

$291.57

-6.97 (-2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 24

    Jul

  • 29

    Jul

  • 03

    Aug

  • 06

    Aug

  • 08

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

CMI

Cummins

$170.04

2.08 (1.24%)

, VWAGY

Volkswagen

$0.00

(0.00%)

12:06
07/19/19
07/19
12:06
07/19/19
12:06
Periodicals
Cummins makes bid for VW's MAN Energy Solutions unit, Reuters says »

Cummins (CMI) has made an…

CMI

Cummins

$170.04

2.08 (1.24%)

VWAGY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

SSRM

SSR Mining

$15.69

-0.04 (-0.25%)

12:05
07/19/19
07/19
12:05
07/19/19
12:05
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

12:05
07/19/19
07/19
12:05
07/19/19
12:05
General news
U.S. Data Slate: The week of July 22 »

U.S. Data Slate: The week…

XOM

Exxon Mobil

$74.86

0.02 (0.03%)

12:04
07/19/19
07/19
12:04
07/19/19
12:04
Periodicals
Exxon Mobil starts process of selling Norwegian oil fields, Bloomberg says »

Exxon Mobil has begun the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

CTK

CooTek

$8.54

-0.02 (-0.23%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
CooTek falls -6.6% »

CooTek is down -6.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHWY

Chewy

$30.63

-2.16 (-6.59%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
Chewy falls -6.8% »

Chewy is down -6.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$5.29

-1.02 (-16.16%)

12:00
07/19/19
07/19
12:00
07/19/19
12:00
Hot Stocks
QEP Resources falls -16.2% »

QEP Resources is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.